OncoMatch/Clinical Trials/NCT05846880
VitD3 Supplementation in Patients With Multiple Myeloma
Is NCT05846880 recruiting? Yes, currently enrolling (May 2026). This Early Phase 1 trial studies multiple treatments including Lenalidomide and Maintenance Vitamin D for multiple myeloma.
Treatment: Lenalidomide · Maintenance Vitamin D · No maintenance Vitamin D — The goal of this clinical trial is to evaluate post-transplant immune reconstitution and lymphocyte recovery as well as the 3-year progression-free survival of patients with multiple myeloma in two treatment arms. One arm will receive Maintenance Vitamin D and the other arm will receive no maintenance Vitamin D prior to ASCT. Post ASCT arm 1 will have lenalidomide and maintenance VitD, and arm 2 will receive lenalidomide and no maintenance VitD. This clinical trial will also evaluate the overall response rate and survival for both treatment arms.
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Performance status
ZUBROD/ECOG 0–2
Zubrod/ECOG Performance Status 2
Prior therapy
Must have received: systemic induction therapy — prior to ASCT
systemic induction therapy prior to ASCT
Cannot have received: allograft
Prior allograft
Cannot have received: organ transplant requiring immunosuppressive therapy
prior organ transplant requiring immunosuppressive therapy
Cannot have received: autologous stem cell transplant
have already received a previous autologous transplantation (e.g., requiring second ASCT at time of screening)
Cannot have received: investigational agent
Received any investigational agents within 14 days prior to registration
Lab requirements
Kidney function
creatinine clearance (CrCl) 10 mL/min., as measured by a 24-hour urine collection, or estimated by the Cockcroft and Gault formula
Liver function
Total bilirubin 1.5 x IULN and AST and ALT 3.0 x IULN
Patients must have evidence of adequate renal function ... CrCl 10 mL/min ... adequate hepatic function ... Total bilirubin 1.5 x IULN and AST and ALT 3.0 x IULN
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Georgia Cancer Center at Augusta University · Augusta, Georgia
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify